This finding challenges the traditional view that a high Ki-67 index—considered a surrogate for tumor aggressiveness—should discourage IBR due to presumed risks of impaired healing or delayed adjuvant therapy [6,8,9,15]. This evidence concerns the gene MKI67 and neoplasm.